{
    "xml": "<topic id=\"PHP5461\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/dacarbazine\" basename=\"dacarbazine\" title=\"DACARBAZINE\">\n<title>DACARBAZINE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1167\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/dacarbazine\">Dacarbazine</xref>\n</p>\n<data name=\"vtmid\">77750008</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_348581499\" title=\"Alkylating agents\">Alkylating agents</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP56106\" outputclass=\"indicationsAndDose\" rev=\"1.24\" parent=\"/drugs/dacarbazine\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Metastatic melanoma</p>\n<p outputclass=\"therapeuticIndication\">Soft tissue sarcomas (combination therapy)</p>\n<p outputclass=\"therapeuticIndication\">Hodgkin's disease (combination therapy)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion or by intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>(consult local protocol).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP56169\" outputclass=\"cautions\" rev=\"1.7\" parent=\"/drugs/dacarbazine\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Caution in handling&#8212;irritant to tissues</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP56100\" outputclass=\"interactions\" rev=\"1.6\" parent=\"/drugs/dacarbazine\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (dacarbazine).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP56060\" outputclass=\"sideEffects\" rev=\"1.22\" parent=\"/drugs/dacarbazine\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Irritant to skin</ph>; <ph outputclass=\"sideEffect\">irritant to tissues</ph>; <ph outputclass=\"sideEffect\">liver necrosis due to hepatic vein thrombosis</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Alopecia</ph>; <ph outputclass=\"sideEffect\">bone-marrow suppression</ph>; <ph outputclass=\"sideEffect\">extravasation</ph>; <ph outputclass=\"sideEffect\">hyperuricaemia</ph>; <ph outputclass=\"sideEffect\">myelosuppression</ph>; <ph outputclass=\"sideEffect\">oral mucositis</ph>; <ph outputclass=\"sideEffect\">severe nausea</ph>; <ph outputclass=\"sideEffect\">severe vomiting</ph>; <ph outputclass=\"sideEffect\">tumour lysis syndrome</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP56162\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/dacarbazine\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Exclude pregnancy before treatment with cytotoxic drugs.</p>\n<p>Contraceptive advice should be given to men and women before cytotoxic therapy begins&#8212;ensure effective contraception during and for at least 6 months after treatment in men or women. </p>\n<p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP56095\" outputclass=\"pregnancy\" parent=\"/drugs/dacarbazine\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid (carcinogenic and teratogenic in <i>animal</i> studies).</p>\n<p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP56173\" outputclass=\"breastFeeding\" parent=\"/drugs/dacarbazine\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Discontinue breast-feeding.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP56113\" outputclass=\"hepaticImpairment\" parent=\"/drugs/dacarbazine\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Dose reduction may be required in combined renal and hepatic impairment.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid in severe impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP56077\" outputclass=\"renalImpairment\" parent=\"/drugs/dacarbazine\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Dose reduction may be required in combined renal and hepatic impairment.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid in severe impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59888\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.12\" parent=\"/drugs/dacarbazine\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p>Dacarbazine is a component of a commonly used combination for Hodgkin's disease (ABVD&#8212;doxorubicin [previously <i>Adriamycin</i>\n<tm tmtype=\"reg\"/>], bleomycin, vinblastine, and dacarbazine).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP5461-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/dacarbazine\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75842\" title=\"Powder for solution for injection\" namespace=\"/drugs/dacarbazine/powder-for-solution-for-injection\">Powder for solution for injection</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75835\" title=\"Powder for solution for infusion\" namespace=\"/drugs/dacarbazine/powder-for-solution-for-infusion\">Powder for solution for infusion</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78537\" namespace=\"/treatment-summaries/cytotoxic-drugs\" title=\"Cytotoxic drugs\" count=\"1\" rel=\"backlink\">Cytotoxic drugs</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1167\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/dacarbazine\" title=\"Dacarbazine\" count=\"1\" rel=\"link\">Dacarbazine</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75842\" namespace=\"/drugs/dacarbazine/powder-for-solution-for-injection\" title=\"Powder for solution for injection\" count=\"1\" rel=\"link\">Powder for solution for injection</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75835\" namespace=\"/drugs/dacarbazine/powder-for-solution-for-infusion\" title=\"Powder for solution for infusion\" count=\"1\" rel=\"link\">Powder for solution for infusion</xref>\n</links>\n</topic>",
    "id": "PHP5461",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/dacarbazine",
    "basename": "dacarbazine",
    "title": "DACARBAZINE",
    "interactants": [
        {
            "id": "bnf_int_1167",
            "label": "Dacarbazine"
        }
    ],
    "vtmid": "77750008",
    "drugClassification": [
        "Alkylating agents"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Metastatic melanoma",
                        "html": "Metastatic melanoma"
                    },
                    {
                        "textContent": "Soft tissue sarcomas (combination therapy)",
                        "html": "Soft tissue sarcomas (combination therapy)"
                    },
                    {
                        "textContent": "Hodgkin's disease (combination therapy)",
                        "html": "Hodgkin's disease (combination therapy)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion or intravenous injection"
                    ],
                    "textContent": "By intravenous infusion or by intravenous injection",
                    "html": "By intravenous infusion or by intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "(consult local protocol).",
                        "html": "<p>(consult local protocol).</p>"
                    }
                ]
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Caution in handling&#8212;irritant to tissues",
                "html": "Caution in handling&#8212;irritant to tissues"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (dacarbazine).",
                "html": "<p>Appendix 1 (dacarbazine).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Irritant to skin",
                        "html": "Irritant to skin",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "irritant to tissues",
                        "html": "irritant to tissues",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "liver necrosis due to hepatic vein thrombosis",
                        "html": "liver necrosis due to hepatic vein thrombosis",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Alopecia",
                        "html": "Alopecia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "bone-marrow suppression",
                        "html": "bone-marrow suppression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "extravasation",
                        "html": "extravasation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hyperuricaemia",
                        "html": "hyperuricaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "myelosuppression",
                        "html": "myelosuppression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "oral mucositis",
                        "html": "oral mucositis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "severe nausea",
                        "html": "severe nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "severe vomiting",
                        "html": "severe vomiting",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "tumour lysis syndrome",
                        "html": "tumour lysis syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Exclude pregnancy before treatment with cytotoxic drugs.\n\nContraceptive advice should be given to men and women before cytotoxic therapy begins&#8212;ensure effective contraception during and for at least 6 months after treatment in men or women.\n\nRegimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.",
                "html": "<p>Exclude pregnancy before treatment with cytotoxic drugs.</p><p>Contraceptive advice should be given to men and women before cytotoxic therapy begins&#8212;ensure effective contraception during and for at least 6 months after treatment in men or women. </p><p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid (carcinogenic and teratogenic in animal studies).\n\nConsiderable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.",
                "html": "<p>Avoid (carcinogenic and teratogenic in <i>animal</i> studies).</p><p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Discontinue breast-feeding.",
                "html": "<p>Discontinue breast-feeding.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Dose reduction may be required in combined renal and hepatic impairment.",
                "html": "<p>Dose reduction may be required in combined renal and hepatic impairment.</p>"
            }
        ],
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid in severe impairment.",
                "html": "<p>Avoid in severe impairment.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Dose reduction may be required in combined renal and hepatic impairment.",
                "html": "<p>Dose reduction may be required in combined renal and hepatic impairment.</p>"
            }
        ],
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid in severe impairment.",
                "html": "<p>Avoid in severe impairment.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "textContent": "Dacarbazine is a component of a commonly used combination for Hodgkin's disease (ABVD&#8212;doxorubicin [previously Adriamycin ], bleomycin, vinblastine, and dacarbazine).",
                "html": "<p>Dacarbazine is a component of a commonly used combination for Hodgkin's disease (ABVD&#8212;doxorubicin [previously <i>Adriamycin</i>\n<tm tmtype=\"reg\"/>], bleomycin, vinblastine, and dacarbazine).</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75842",
                "label": "Powder for solution for injection",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75835",
                "label": "Powder for solution for infusion",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78537",
                "label": "Cytotoxic drugs",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1167",
                "label": "Dacarbazine",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75842",
                "label": "Powder for solution for injection",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75835",
                "label": "Powder for solution for infusion",
                "type": "medicinalForm"
            }
        ]
    }
}